Copyright
©The Author(s) 2022.
World J Gastroenterol. Aug 28, 2022; 28(32): 4493-4507
Published online Aug 28, 2022. doi: 10.3748/wjg.v28.i32.4493
Published online Aug 28, 2022. doi: 10.3748/wjg.v28.i32.4493
Table 2 The sensitivity and specificity of the screening tests for celiac disease
| Test | Sensitivity | Specificity |
| Anti-tissue transglutaminase antibody[97] | 92.8% (95%CI: 90.3-94.8) | 97.9% (95%CI: 96.4- 98.8) |
| Anti-endomysial antibody[97] | 73% (95%CI: 61-83) | 99.0% (95%CI 98.0-99.0) |
| Deamidated gliadin peptide antibodies[97] | 87.8% (95%CI: 85.6-89.9) | 94.1% (95%CI: 92.5-95.5) |
| Point-of care tests (107) | ||
| Anti-anti-tissue transglutaminase antibody + Anti-gliadin antibody | 94.0% (95%CI: 89.9-96.5) | 94.4% (95%CI: 90.9-96.5) |
| IgA anti-tissue transglutaminase antibody | 90.5% (95%CI: 82.3-95.1) | 94.8% (95%CI: 92.5-96.4) |
- Citation: Singh P, Singh AD, Ahuja V, Makharia GK. Who to screen and how to screen for celiac disease. World J Gastroenterol 2022; 28(32): 4493-4507
- URL: https://www.wjgnet.com/1007-9327/full/v28/i32/4493.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i32.4493